Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Gains from Investment Securities (2022 - 2025)

CervoMed's Gains from Investment Securities history spans 6 years, with the latest figure at $995374.0 for Q3 2025.

  • For Q3 2025, Gains from Investment Securities rose 2405.91% year-over-year to $995374.0; the TTM value through Sep 2025 reached $995374.0, up 2405.91%, while the annual FY2024 figure was $636802.0, 82.27% up from the prior year.
  • Gains from Investment Securities for Q3 2025 was $995374.0 at CervoMed, up from $54000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $995374.0 in Q3 2025 and bottomed at $274.0 in Q1 2022.
  • The 4-year median for Gains from Investment Securities is $141500.0 (2022), against an average of $296998.3.
  • The largest annual shift saw Gains from Investment Securities plummeted 62.85% in 2023 before it skyrocketed 2405.91% in 2025.
  • A 4-year view of Gains from Investment Securities shows it stood at $349374.0 in 2022, then changed by 0.0% to $349374.0 in 2023, then soared by 82.27% to $636802.0 in 2024, then surged by 56.31% to $995374.0 in 2025.
  • Per Business Quant, the three most recent readings for CRVO's Gains from Investment Securities are $995374.0 (Q3 2025), $54000.0 (Q2 2025), and $909448.0 (Q1 2025).